The HDAC inhibitors panobinostat and vorinostat are epigenetic drugs that can be combined with other agents.
Panobinostat had a significant advantage when combined with bortezomib and dexamethasone over the same drugs with placebo; at the cost, however, of gastrointestinal symptoms and fatigue. Panobinostat combined with bortezomib and dexamethasone has been approved by the EMA for use in RRMM patients.
Footnotes
Information on authorship, contributions, and financial & other disclosures was provided by the authors and is available with the online version of this article at www.haematologica.org.